Q-omics provides the consensus-scored CCDC43 profile across patient tissues and cancer cell-line models. CCDC43 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC43 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, CCDC43 RNA expression shows 19,626 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where CCDC43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC43 survival associations across molecular data types. CCDC43 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC43 RNA expression–survival associations across cancer types. High CCDC43 expression shows unfavorable associations in HNSC, CESC, ACC, LIHC and KIRP, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC43 RNA expression.
This table summarizes CCDC43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC43 shows higher tumor expression in HNSC, KIRC, BLCA, KIRP, LIHC and STAD. The HNSC box plot shows higher CCDC43 RNA expression in tumor versus normal tissue (log2 FC = +0.790, t-test p < 0.001).
This table shows molecular features associated with CCDC43 in patient tissues and cancer cell lines. In patient samples, CCDC43 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
